• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

何时以及如何将新技术引入 IVF 实验室?

When and how should new technology be introduced into the IVF laboratory?

机构信息

UCL Centre for PG&D, Institute for Womens Health, UCL and Centre for Reproductive and Genetic Health, University College London Hospital, London, UK.

出版信息

Hum Reprod. 2012 Feb;27(2):303-13. doi: 10.1093/humrep/der414. Epub 2011 Dec 12.

DOI:10.1093/humrep/der414
PMID:22166806
Abstract

There are many examples in assisted reproduction technology, where new technology and methods have been introduced into the clinical setting without appropriate development and evidence-based medicine to show that the procedure is safe and beneficial to the patient. Examples include preimplantation genetic screening, assisted hatching, in vitro maturation, blastocyst transfer and vitrification. Changes to culture media composition, stimulation regimes and laboratory protocols are also often established internationally without adequate validation. More recently, novel equipment that needs to be validated before it enters routine clinical use is being developed for IVF. With technologies such as producing gametes from stem cells around the corner, it is vital to ensure that the necessary research and development is conducted before bringing new techniques into clinical practice. Ideally, this should include preliminary work on animal models, such as mice/rats/rabbits/larger mammals, followed by studies on human embryos donated for research and finally well-designed RCTs with a follow up of all children born from the procedure. If such preliminary studies are not performed and published, it is possible that technology bringing no clinical benefit or leading to adverse health outcomes in the children born by these practices may be introduced. All IVF clinics need to consider the safety and efficacy of new technologies before introducing them.

摘要

在辅助生殖技术中有许多例子,新技术和方法被引入临床应用,而没有适当的开发和循证医学来证明该程序对患者是安全和有益的。例如,植入前遗传学筛查、辅助孵化、体外成熟、囊胚转移和玻璃化。培养基成分、刺激方案和实验室方案的改变也经常在没有充分验证的情况下在国际上建立。最近,为了 IVF,正在开发需要在常规临床使用前进行验证的新型设备。随着干细胞产生配子等技术的临近,在将新技术引入临床实践之前,确保进行必要的研究和开发至关重要。理想情况下,这应包括在动物模型(如小鼠/大鼠/兔子/较大的哺乳动物)上进行初步研究,然后在为研究捐赠的人类胚胎上进行研究,最后是设计良好的 RCT,并对该程序产生的所有儿童进行随访。如果没有进行和发表这些初步研究,那么可能会引入没有临床益处或导致通过这些实践出生的儿童健康结果不良的技术。所有 IVF 诊所都需要在引入新技术之前考虑其安全性和有效性。

相似文献

1
When and how should new technology be introduced into the IVF laboratory?何时以及如何将新技术引入 IVF 实验室?
Hum Reprod. 2012 Feb;27(2):303-13. doi: 10.1093/humrep/der414. Epub 2011 Dec 12.
2
Pregnancy outcomes after assisted human reproduction.人类辅助生殖后的妊娠结局
J Obstet Gynaecol Can. 2014 Jan;36(1):64-83. doi: 10.1016/S1701-2163(15)30685-X.
3
How should we assess the safety of IVF technologies?我们应该如何评估试管婴儿技术的安全性?
Reprod Biomed Online. 2013 Dec;27(6):710-21. doi: 10.1016/j.rbmo.2013.09.006. Epub 2013 Sep 14.
4
The human embryo in vitro: recent progress.体外培养的人类胚胎:近期进展
J Reprod Med. 2006 Apr;51(4):293-302.
5
IVF versus ICSI for the fertilization of in-vitro matured human oocytes.体外成熟卵母细胞的 IVF 与 ICSI 受精比较。
Reprod Biomed Online. 2012 Dec;25(6):603-7. doi: 10.1016/j.rbmo.2012.08.001. Epub 2012 Aug 31.
6
The complex microbiome from native semen to embryo culture environment in human in vitro fertilization procedure.人类体外受精程序中从天然精液到胚胎培养环境的复杂微生物组。
Reprod Biol Endocrinol. 2020 Jan 16;18(1):3. doi: 10.1186/s12958-019-0562-z.
7
Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial.胞浆内单精子注射与常规体外受精治疗男方总精子数和活力正常的不育夫妇的比较:一项开放标签、随机对照试验。
Lancet. 2021 Apr 24;397(10284):1554-1563. doi: 10.1016/S0140-6736(21)00535-3.
8
Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts.多中心前瞻性研究 1301 个人类囊胚的胚胎游离 DNA 与滋养层活检的一致性。
Am J Obstet Gynecol. 2020 Nov;223(5):751.e1-751.e13. doi: 10.1016/j.ajog.2020.04.035. Epub 2020 May 26.
9
Offspring physiology following the use of IVM, IVF and ICSI: a systematic review and meta-analysis of animal studies.使用 IVM、IVF 和 ICSI 后的后代生理学:动物研究的系统评价和荟萃分析。
Hum Reprod Update. 2023 May 2;29(3):272-290. doi: 10.1093/humupd/dmac043.
10
Multivariate analysis of the factors associated with live births during in vitro fertilisation in Southeast Asia: a cross-sectional study of 104,015 in vitro fertilisation records in Taiwan.多变量分析与体外受精活产相关的因素:对台湾 104015 例体外受精记录的横断面研究。
J Assist Reprod Genet. 2021 Sep;38(9):2415-2423. doi: 10.1007/s10815-021-02086-4. Epub 2021 Jun 1.

引用本文的文献

1
Commercial Impacts on Assisted Reproductive Technology: A Scoping Review.商业对辅助生殖技术的影响:一项范围综述
J Bioeth Inq. 2025 Sep 11. doi: 10.1007/s11673-025-10456-1.
2
Morphometric Blastocyst Assessment: A Retrospective Study Examining the Relationship Between Blastocyst Diameter and Area and Pregnancy Outcomes in Assisted Reproduction Technology Cycles.形态学囊胚评估:一项回顾性研究,探讨辅助生殖技术周期中囊胚直径和面积与妊娠结局之间的关系。
J Clin Med. 2025 Apr 19;14(8):2827. doi: 10.3390/jcm14082827.
3
Application of a methodological framework for the development and multicenter validation of reliable artificial intelligence in embryo evaluation.
一种用于胚胎评估中可靠人工智能开发和多中心验证的方法框架的应用。
Reprod Biol Endocrinol. 2025 Jan 31;23(1):16. doi: 10.1186/s12958-025-01351-w.
4
New Insights on In Vitro Maturation of Oocytes for Fertility Preservation.卵母细胞体外成熟用于生育力保存的新见解。
Int J Mol Sci. 2024 Oct 1;25(19):10605. doi: 10.3390/ijms251910605.
5
A review of artificial intelligence applications in in vitro fertilization.人工智能在体外受精中的应用综述。
J Assist Reprod Genet. 2025 Jan;42(1):3-14. doi: 10.1007/s10815-024-03284-6. Epub 2024 Oct 14.
6
[Some present and future ethical dilemmas surrounding advancements in in vitro fertilization.].[围绕体外受精技术进步的一些当前和未来的伦理困境。]
Salud Colect. 2023 Nov 16;19:e4462. doi: 10.18294/sc.2023.4462.
7
Good practice recommendations on add-ons in reproductive medicine†.生殖医学附加治疗的良好实践建议†。
Hum Reprod. 2023 Nov 2;38(11):2062-2104. doi: 10.1093/humrep/dead184.
8
Artificial Intelligence in Reproductive Medicine - An Ethical Perspective.生殖医学中的人工智能——伦理视角
Geburtshilfe Frauenheilkd. 2023 Jan 11;83(1):106-115. doi: 10.1055/a-1866-2792. eCollection 2023 Jan.
9
Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic.初始可遗传基因组编辑:从基础研究到临床的负责任途径图谱。
Med Health Care Philos. 2023 Mar;26(1):21-35. doi: 10.1007/s11019-022-10115-x. Epub 2022 Nov 22.
10
ESHRE certification of ART centres for good laboratory and clinical practice.ESHRE 对辅助生殖技术中心进行良好实验室和临床实践认证。
Hum Reprod Open. 2022 Sep 14;2022(4):hoac040. doi: 10.1093/hropen/hoac040. eCollection 2022.